ADC Technology Market

ADC Technology Market: Focus on ADC Linker and ADC Conjugation Technologies (2nd Edition) - Distribution by Generation of ADC Technology, Type of Conjugation, Type of Linker and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

  • Lowest Price Guaranteed From USD 4,799

  • Companies Covered
    320

  • Pages
    345

  • View Count
    23371

Table Of Contents

1. PREFACE
1.1. Introduction
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2 Antibody Drug Conjugates (ADCs)
3.2.1 Components of ADCs
3.2.1.1 Antibody
3.2.1.2 Cytotoxin
3.2.1.3 Linker

3.3. Advantages of ADCs Over Conventional Therapeutics
3.4. ADC Linker Technologies
3.4.1. Non-cleavable Linkers
3.4.2. Cleavable Linkers

3.4. ADC Conjugation Technologies
3.4.1. Chemical Conjugation
3.4.2. Enzymatic Conjugation

3.5. Future Perspectives

4. ADC LINKER AND CONJUGATION TECHNOLOGIES: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. ADC Linker and Conjugation Technologies: Overall Market Landscape
4.2.1. Analysis by Type of Technology
4.2.2. Analysis by Availability of Licensing

4.3. ADC Conjugation Technologies
4.3.1. Analysis by Generation of Technology
4.3.2. Analysis by Site Specificity
4.3.3. Analysis by Type of Conjugation
4.3.4. Analysis by Drug Antibody Ratio
4.3.5. Analysis by Compatible Linker
4.3.6. Analysis by Conjugation Chemistry
4.3.7. Analysis by Conjugation Site

4.4. ADC Linker and ADC Linker-Payload Technologies
4.4.1. Analysis by Type of Linker

4.5. ADC Linker and Conjugation Technology Providers
4.5.1. Analysis by Year of Establishment
4.5.2. Analysis by Company Size
4.5.3. Analysis by Location of Headquarters
4.5.4. Analysis by Year of Establishment and Location of Headquarters
4.5.5. Analysis by Company Size and Location of Headquarters

4.6. ADC Conjugation Technologies Service Providers

5. TECHNOLOGY COMPETITIVENESS ANALYSIS
5.1 Chapter Overview
5.2 Assumptions and Key Parameters
5.3 Methodology
5.4 ADC Linker and Conjugation Technologies: Technology Competitiveness Analysis
5.4.1 Technologies Offered by Small Companies
5.4.2 Technologies Offered by Mid-sized Companies
5.4.3 Technologies Offered by Large Companies

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Companies Headquartered in North America
6.2.1. Ambrx
6.2.1.2. Company Overview
6.2.1.3. Financial Information
6.2.1.4. Technology Portfolio
6.2.1.5. Recent Developments and Future outlook

6.2.2. Catalent Biologics
6.2.2.1. Company Overview
6.2.2.2. Financial Information
6.2.2.3. Technology Portfolio
6.2.2.4. Recent Developments and Future outlook

6.2.3. Mersana Therapeutics
6.2.3.1. Company Overview
6.2.3.2. Financial Information
6.2.3.3. Technology Portfolio
6.2.3.4. Recent Developments and Future outlook

6.2.4. Seagen
6.2.4.1. Company Overview
6.2.4.2. Financial Information
6.2.4.3. Technology Portfolio
6.2.4.4. Recent Developments and Future outlook

6.2.5. Sutro Biopharma
6.2.5.1. Company Overview
6.2.5.2. Financial Information
6.2.5.3. Technology Portfolio
6.2.5.4. Recent Developments and Future outlook

6.3. Companies Headquartered in Europe
6.3.1. Antikor Biopharma
6.3.1.1. Company Overview
6.3.1.2. Technology Portfolio
6.3.1.3. Recent Developments and Future outlook

6.3.2. Iksuda Therapeutics
6.3.2.1. Company Overview
6.3.2.2. Technology Portfolio
6.3.2.3. Recent Developments and Future outlook

6.3.3. Heidelberg Pharma
6.3.3.1. Company Overview
6.3.3.2. Financial Information
6.3.3.3. Technology Portfolio
6.3.3.4. Recent Developments and Future outlook

6.3.4. LinXis Biopharmaceuticals
6.3.4.1. Company Overview
6.3.4.2. Technology Portfolio
6.3.4.3. Recent Developments and Future outlook

6.3.5. NBE-Therapeutics
6.3.5.1. Company Overview
6.3.5.2. Technology Portfolio
6.3.5.3. Recent Developments and Future outlook

6.4. Companies Headquartered in Asia-Pacific and Rest of the World
6.4.1. Alteogen
6.4.1.1. Company Overview
6.4.1.2. Technology Portfolio
6.4.1.3. Recent Developments and Future outlook

6.5.2. LegoChem Biosciences
6.5.2.1. Company Overview
6.5.2.2. Technology Portfolio
6.5.2.3. Recent Developments and Future outlook

7. PATENT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. ADC Linker and Conjugation Technologies: Patent Analysis
7.3.1. Analysis by Publication Year
7.3.2. Analysis by Application Year
7.3.3. Analysis by Annual Number of Granted Patents and Patent Applications
7.3.4. Analysis by Patent Jurisdiction
7.3.5. Analysis by CPC Symbols and Sections
7.3.6. Analysis by Type of Applicant
7.3.7. Leading Industry Players: Analysis by Number of Patents
7.3.8. Leading Non-Industry Players: Analysis by Number of Patents
7.3.9. Leading Patent Assignees: Analysis by Number of Patents

7.4. Patent Benchmarking Analysis
7.4.1. Analysis by Patent Characteristics

7.5. Patent Valuation
7.6. Leading Patents by Number of Citations

8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. ADC Linker and Conjugation Technologies: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year of Partnership and Type of Partnership
8.3.4. Analysis by Type of Partnership and Generation of Technology
8.3.5. Analysis by Type of Partnership and Type of Linker
8.3.6. Analysis by Type of Partnership and Type of Conjugation
8.3.7. Analysis by Type of Partner
8.3.8. Analysis by Year of Partnership and Type of Partner
8.3.9. Analysis by Type of Partnership and Type of Partner
8.3.10. Analysis by Target Therapeutic Area(s)
8.3.11. Most Active Players: Analysis by Number of Partnerships
8.3.12. Most Popular Technologies: Analysis by Number of Partnerships

8.4. Regional Analysis
8.4.1. Local and International Agreements
8.4.12. Intercontinental and Intracontinental Agreements

9. BUSINESS MODEL ANALYSIS
9.1. Chapter Overview
9.2 Business Strategies
9.4. ADC Linker and Conjugation Technology Providers: Business Strategy Analysis
9.4.1. Analysis by Purpose of Partnership
9.4.2. Analysis by Year of Partnership and Purpose of Partnership
9.4.3. Analysis by Type of Business Strategy Adopted
9.4.4. Analysis by Purpose of Partnership and Type of Business Strategy Adopted
9.4.5. Analysis by Upfront and Milestone Payments
9.4.6. Analysis by Type of Business Strategy Adopted and Deal Value

9.5. Most Active Players: Analysis by Number of Partnerships
9.5.1. Synaffix
9.5.1.1. Analysis by Purpose of Partnership
9.5.1.2. Analysis of Technology Out-Licensing Deals by Deal Value

9.5.2. LegoChem Biosciences
9.5.2.1. Analysis by Purpose of Partnership
9.5.2.2. Analysis by Year of Partnership and Business Strategy Adopted
9.5.2.3. Analysis of Technology Out-Licensing Deals by Amount of Investment

9.5.3. Catalent Biologics
9.5.3.1. Analysis by Purpose of Partnership
9.5.3.2. Analysis by Year of Partnership and Business Strategy Adopted

9.5.4. Sutro Biopharma
9.5.4.1. Analysis by Purpose of Partnership
9.5.4.2. Analysis by Year of Partnership and Business Strategy Adopted
9.5.4.3. Analysis of Technology Out-Licensing Deals by Deal Value

9.5.5. Heidelberg Pharma
9.5.5.1. Analysis by Purpose of Partnership
9.5.5.2. Analysis by Year of Partnership and Business Strategy Adopted

9.5.6. Mersana Therapeutics
9.5.6.1. Analysis by Purpose of Partnership
9.5.6.2. Analysis by Year of Partnership and Business Strategy Adopted

9.7. Concluding Remarks

10. LIKELY PARTNERS ANALYSIS
10.1. Chapter Overview
10.2. Assumptions / Key Parameters
10.3. Scope and Methodology

10.4. Potential Strategic Partners in North America
10.4.1. Most Likely Partners
10.4.2. Likely Partners
10.4.3. Less Likely Partners
10.4.4. Least Likely Partners

10.5. Potential Strategic Partners in Europe
10.5.1. Most Likely Partners
10.5.2. Likely Partners
10.5.3. Less Likely Partners
10.5.4. Least Likely Partners

10.6. Potential Strategic Partners in Asia-Pacific and Rest of the World
10.6.1. Most Likely Partners
10.6.2. Likely Partners
10.6.3. Less Likely Partners
10.6.4. Least Likely Partners

11. BRAND POSITIONING ANALYSIS
11.1. Chapter Overview
11.2 Scope and Methodology
11.3. Key Parameters
11.4. Brand Positioning Matrix: ADC Conjugation Technology Providers
11.4.1. Brand Positioning Matrix: Abzena
11.4.2. Brand Positioning Matrix: Ambrx
11.4.3. Brand Positioning Matrix: Byondis
11.4.4. Brand Positioning Matrix: Creative Biolabs
11.4.5. Brand Positioning Matrix: Eisai
11.4.6. Brand Positioning Matrix: Mersana Therapeutics
11.4.7. Brand Positioning Matrix: Sorrento Therapeutics
11.4.8. Brand Positioning Matrix: Tubulis

12. ADC THERAPEUTICS: MARKET LANDSCAPE
12.1. Chapter Overview
12.2. Antibody Drug Conjugates: Therapies Pipeline
12.2.1. Analysis by Stage of Development
12.2.2. Analysis by Target Disease Indication(s)
12.2.3. Analysis by Therapeutic Area(s)
12.2.4. Analysis by Line of Treatment
12.2.5. Analysis by Dosing Frequency
12.2.6. Analysis by Type of Therapy
12.2.7. Analysis by Target Antigen
12.2.8. Analysis by Antibody Isotype
12.2.9. Analysis by Type of Payload / Cytotoxin / Warhead
12.2.10. Analysis by Type of Payload
12.2.11. Analysis by Linker
12.2.12. Analysis by Type of Linker (Cleavable / Non-Cleavable)

12.3. Antibody Drug Conjugate: List of Developers
12.3.1. Analysis by Year of Establishment
12.3.2. Analysis by Company Size
12.3.3. Analysis by Location of Headquarters
12.3.4. Analysis by Company size and Location of Headquarters
12.3.5. Most Active Players: Analysis by Number of Therapies

13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions
13.3. Forecast Methodology
13.4. Global ADC Linker and Conjugation Technologies Market, Historical, Base and Forecasted Scenario, 2017-2035
13.4.1. ADC Linker and Conjugation Technologies Market: Distribution by Generation of Technology, 2023 and 2035
13.4.1.1. ADC Linker and Conjugation Technologies Market for Third-Generation Technologies 2023-2035
13.4.1.2. ADC Linker and Conjugation Technologies Market for Second-Generation Technologies 2023-2035
13.4.1.3. ADC Linker and Conjugation Technologies Market for Next-Generation Technologies, 2023-2035

13.4.2. ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, 2023 and 2035
13.4.2.1. ADC Linker and Conjugation Technologies Market for Chemical Conjugation, 2023-2035
13.4.2.2. ADC Linker and Conjugation Technologies Market for Chemoenzymatic Conjugation, 2023-2035
13.4.2.3. ADC Linker and Conjugation Technologies Market for Enzymatic Conjugation, 2023-2035

13.4.3. ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, 2023 and 2035
13.4.3.1. ADC Linker and Conjugation Technologies Market for Cleavable Linkers, 2023-2035
13.4.3.2. ADC Linker and Conjugation Technologies Market for Non-Cleavable Linkers, 2023-2035

13.4.4. ADC Linker and Conjugation Technologies Market: Distribution by Type of Payment Model Adopted, 2023 and 2035
13.4.4.1. ADC Linker and Conjugation Technologies Market for Upfront Payments, 2023-2035
13.4.4.2. ADC Linker and Conjugation Technologies Market for Milestone Payments, 2023-2035

13.4.5. ADC Linker and Conjugation Technologies Market: Distribution by Key Geographical Regions, 2023 and 2035
13.4.5.1. ADC Linker and Conjugation Technologies Market in North America, 2023-2035
13.4.5.1.1. ADC Linker and Conjugation Technologies Market in North America: Distribution by Generation of Technology, 2023-2035
13.4.5.1.2. ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Conjugation, 2023-2035
13.4.5.1.3. ADC Linker and Conjugation Technologies Market in North America: Distribution by Type Linker, 2023-2035

13.4.5.2. ADC Linker and Conjugation Technologies Market in Europe, 2023-2035
13.4.5.2.1. ADC Linker and Conjugation Technologies Market in Europe: Distribution by Generation of Technology, 2023-2035
13.4.5.2.2. ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Conjugation, 2023-2035
13.4.5.2.3. ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type Linker, 2023-2035

13.4.5.3. ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World, 2023-2035
13.4.5.3.1. ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Generation of Technology, 2023-2035
13.4.5.3.2. ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type of Conjugation, 2023-2035
13.4.5.3.3. ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type of Linker, 2023-2035

13.5. Concluding Remarks

14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. Abzena
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Scientist II

14.3. MedLink Therapeutics
14.3.1. Company Snapshot
14.3.2. Interview Transcript: Chief Scientific Officer

14.4. Merck KGaA
14.4.1. Company Snapshot
14.4.2. Interview Transcript: Head of Business Development)

14.5. Singzyme
14.5.1. Company Snapshot
14.5.2. Interview Transcript: Board Member

14.6. Ajinomoto
14.6.1. Company Snapshot
14.6.2. Interview Transcript: General Manager, Research and Development, Director of ADC Process Development

14.7. Eucodis Bioscience
14.7.1. Company Snapshot
14.7.2. Interview Transcript: Head of Research

14.8. NBE-Therapeutics
14.8.1. Company Snapshot
14.8.2. Interview Transcript: Former Chief Business Officer

14.9. Shanghai Miracogen
14.9.1. Company Snapshot
14.9.2. Interview Transcript: Chief Executive Officer

14.10. Synaffix
14.10.1. Company Snapshot
14.10.2. Interview Transcript: Chief Scientific Officer

15. CONCLUDING REMARKS

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Current Market Landscape of ADC Linker and Conjugation Technologies
Figure 2.2 Executive Summary: Patent Analysis
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Business Model Analysis
Figure 2.5 Executive Summary: Case Study on ADC Therapeutics
Figure 2.6 Executive Summary: Market Sizing and Opportunity Analysis
Figure 3.1. Components of ADCs
Figure 3.2. Types of Linkers
Figure 4.1. ADC Linker and Conjugation Technologies: Distribution by Type of Technology
Figure 4.2. ADC Linker and Conjugation Technologies: Distribution by Availability of  Licensing
Figure 4.3. ADC Conjugation Technologies: Distribution by Generation of Technology
Figure 4.4. ADC Conjugation Technologies: Distribution by Site Specificity
Figure 4.5. ADC Conjugation Technologies: Distribution by Type of Conjugation
Figure 4.6. ADC Conjugation Technologies: Distribution by Drug Antibody Ratio
Figure 4.7. ADC  Conjugation Technologies: Distribution by Compatible Linker
Figure 4.8. ADC  Conjugation Technologies: Distribution by Conjugation Chemistry
Figure 4.9. ADC  Conjugation Technologies: Distribution by Conjugation Site 
Figure 4.10. ADC Linker and ADC Linker-Payload Technologies: Distribution by Type of Linker
Figure 4.11. ADC Linker and Conjugation Technology Providers: Distribution by Year of Establishment
Figure 4.12 ADC Linker and Conjugation Technology Providers: Distribution by Company Size
Figure 4.13. ADC Linker and Conjugation Technology Providers: Distribution by Location of Headquarters
Figure 4.14. ADC Linker and Conjugation Technology Providers: Distribution by Year of Establishment and Location of Headquarters
Figure 4.15. ADC Linker and Conjugation Technology Providers: Distribution by Company Size and Location of Headquarters 
Figure 5.1 Technology Competitiveness Analysis: Distribution of Technologies Offered by Small Companies
Figure 5.2 Technology Competitiveness Analysis: Distribution of Technologies Offered by Mid-sized Companies
Figure 5.3 Technology Competitiveness Analysis: Distribution of Technologies Offered by Large Companies
Figure 6.1 Ambrx: Annual Revenues, 2020-2022 (USD Million)
Figure 6.2 Catalent Biologics: Revenues, 2018- 2022 (USD Billion)
Figure 6.3. Mersana Therapeutics: Annual Revenues, 2018-2022 (USD Million)
Figure 6.4 Seagen: Revenues, 2018-2022 (USD Billion)
Figure 6.5 Sutro Biopharma: Revenues, 2018 - 2022 (KRW Billion)
Figure 6.6 Heidelberg Pharma: Annual Revenues, 2018-2022 (EUR Million)
Figure 7.1. Patent Analysis: Distribution by Type of Patent
Figure 7.2. Patent Analysis: Cumulative Distribution by Publication Year
Figure 7.3. Patent Analysis: Cumulative Distribution by Application Year
Figure 7.4. Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications
Figure 7.5. Patent Analysis: Distribution by Patent Jurisdiction
Figure 7.6. Patent Analysis: Distribution by CPC Symbols and Sections
Figure 7.7. Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Figure 7.9. Leading Industry Players: Distribution by Number of Patents
Figure 7.10. Leading Non-Industry Players: Distribution by Number of Patents
Figure 7.11. Leading Patent Assignees: Distribution by Number of Patents
Figure 7.12. Patent Benchmarking Analysis: Distribution of Leading Industry Player by Patent Characteristics (CPC Codes)
Figure 7.13. Patent Analysis: Distribution by Patent Age
Figure 7.14. ADC Linker and Conjugation Technologies: Patent Valuation
Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership and Generation of Technology
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Linker
Figure 8.6. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Conjugation
Figure 8.7. Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.8. Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 8.9. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 8.10. Partnerships and Collaborations: Distribution by Therapeutic Area(s)
Figure 8.11. Most Active Players: Distribution by Number of Partnerships
Figure 8.12. Most Popular Technologies: Distribution by Number of Partnerships
Figure 8.13 Partnerships and Collaborations: Local and International Agreements
Figure 8.14 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 Business Models Analysis: Distribution by Purpose of Partnership
Figure 9.2 Business Models Analysis: Year-wise Distribution by Purpose of Partnership
Figure 9.3 Business Models Analysis: Distribution by Type of Business Strategy Adopted
Figure 9.4 Business Models Analysis: Distribution by Purpose of Partnership and Type of Business Strategy Adopted
Figure 9.5 Business Models Analysis: Distribution by Upfront and Milestone Payments
Figure 9.6. Business Models Analysis: Distribution by Type of Business Strategy Adopted and Deal Value
Figure 9.7. Synaffix: Distribution by Purpose of Partnership
Figure 9.8. Synaffix: Distribution of Technology Out-Licensing Deals by Deal Value
Figure 9.9. LegoChem Biosciences: Distribution by Purpose of Partnership
Figure 9.10. LegoChem Biosciences: Distribution by Year of Partnership and Business Strategy Adopted
Figure 9.11. LegoChem Biosciences: Distribution of Technology Out-Licensing Deals by Deal Value
Figure 9.12. Catalent Biologics: Distribution by Purpose of Partnership
Figure 9.13. Catalent Biologics: Distribution by Year of Partnership and Business Strategy Adopted
Figure 9.14. Sutro Biopharma: Distribution by Purpose of Partnership
Figure 9.15. Sutro Biopharma: Distribution by Year of Partnership and Business Strategy Adopted
Figure 9.16. Sutro Biopharma: Distribution of Technology Out-Licensing Deals by Deal Value
Figure 9.17. Heidelberg Pharma: Distribution by Purpose of Partnership
Figure 9.18. Heidelberg Pharma: Distribution by Year of Partnership and Business Strategy Adopted
Figure 9.19. Mersana Therapeutics: Distribution by Purpose of Partnership
Figure 9.20. Mersana Therapeutics: Distribution by Year of Partnership and Business Strategy Adopted
Figure 11.1 Brand Positioning Analysis: Competitive Advantage
Figure 11.2 Brand Positioning Analysis: Reasons to Believe
Figure 11.3 Brand Positioning Matrix: Abzena
Figure 11.4 Brand Positioning Matrix: Ambrx
Figure 11.5 Brand Positioning Matrix: Byondis
Figure 11.6. Brand Positioning Matrix: Creative Biolabs
Figure 11.7. Brand Positioning Matrix: Eisai
Figure 11.8. Brand Positioning Matrix: Mersana Therapeutics
Figure 11.9. Brand Positioning Matrix: Sorrento Therapeutics
Figure 11.10. Brand Positioning Matrix: Tubulis
Figure 12.1. Antibody Drug Conjugates: Distribution by Stage of Development
Figure 12.2. Antibody Drug Conjugates: Distribution by Target Disease Indication(s)
Figure 12.3. Antibody Drug Conjugates: Distribution by Therapeutic Area(s)
Figure 12.4. Antibody Drug Conjugates: Distribution by Line of Treatment
Figure 12.5. Antibody Drug Conjugates: Distribution by Dosing Frequency
Figure 12.6. Antibody Drug Conjugates: Distribution by Type of Therapy
Figure 12.7. Antibody Drug Conjugates: Distribution by Target Antigen
Figure 12.8. Antibody Drug Conjugates: Distribution by Antibody Isotype
Figure 12.9. Antibody Drug Conjugates: Distribution by Type of Cytotoxin / Warhead
Figure 12.10. Antibody Drug Conjugates: Distribution by Type of Payload
Figure 12.11. Antibody Drug Conjugates: Distribution by Linker
Figure 12.12 Antibody Drug Conjugates: Distribution by Type of Linker
Figure 12.13. Antibody Drug Conjugate Developers: Distribution by Year of Establishment
Figure 12.14. Antibody Drug Conjugates Developers: Distribution by Company Size
Figure 12.15. Antibody Drug Conjugates Developers: Distribution by Location of Headquarters
Figure 12.16. Antibody Drug Conjugates Developers: Distribution by Company Size and Location of Headquarters
Figure 12.17. Most Active Players: Distribution by Number of Therapies
Figure 13.1 Licensing Agreements: Distribution of Financial Components
Figure 13.2 Technology Licensing Deal: Payment Structure
Figure 13.3 Global ADC Linker and Conjugation Technologies Market, Historical, Base and Forecasted Scenario, 2023-2035 (USD Million)
Figure 13.4 ADC Linker and Conjugation Technologies Market: Distribution by Generation of Technology, 2023 and 2035
Figure 13.5 ADC Linker and Conjugation Technologies Market for Third-Generation Technologies, 2023-2035 (USD Million)
Figure 13.6 ADC Linker and Conjugation Technologies Market for Second-Generation Technologies, 2023-2035 (USD Million)
Figure 13.7 ADC Linker and Conjugation Technologies Market for Next-Generation Technologies, 2023-2035 (USD Million)
Figure 13.8 ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, 2023 and 2035
Figure 13.9 ADC Linker and Conjugation Technologies Market for Chemical Conjugation, 2023-2035 (USD Million)
Figure 13.10 ADC Linker and Conjugation Technologies Market for Chemoenzymatic Conjugation, 2023-2035 (USD Million)
Figure 13.11 ADC Linker and Conjugation Technologies Market for Enzymatic Conjugation, 2023-2035 (USD Million)
Figure 13.12 ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, 2023 and 2035
Figure 13.13 ADC Linker and Conjugation Technologies Market for Cleavable Linkers, 2023-2035 (USD Million)
Figure 13.14 ADC Linker and Conjugation Technologies Market for Non-Cleavable Linkers, 2023-2035 (USD Million)
Figure 13.15 ADC Linker and Conjugation Technologies Market: Distribution by Type of Payment Model Adopted, 2023 and 2035
Figure 13.16 ADC Linker and Conjugation Technologies Market for Upfront Payments, 2023-2035 (USD Million)
Figure 13.17 ADC Linker and Conjugation Technologies Market for Milestone Payments, 2023-2035 (USD Million)
Figure 13.18 ADC Linker and Conjugation Technologies Market: Distribution by Key Geographical Regions, 2023 and 2035
Figure 13.19 ADC Linker and Conjugation Technologies Market in North America, 2023-2035 (USD Million)
Figure 13.20 ADC Linker and Conjugation Technologies Market in North America: Distribution by Generation of Technology, 2023-2035 (USD Million)
Figure 13.21 ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Conjugation, 2023-2035 (USD Million)
Figure 13.22 ADC Linker and Conjugation Technologies Market in North America: Distribution by Type Linker, 2023-2035 (USD Million)
Figure 13.23 ADC Linker and Conjugation Technologies Market in Europe, 2023-2035 (USD Million)
Figure 13.24 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Generation of Technology, 2023-2035 (USD Million)
Figure 13.25 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Conjugation, 2023-2035 (USD Million)
Figure 13.26 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type Linker, 2023-2035 (USD Million)
Figure 13.27 ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World, 2023-2035 (USD Million)
Figure 13.28 ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Generation of Technology, 2023-2035 (USD Million)
Figure 13.29 ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type of Conjugation, 2023-2035 (USD Million)
Figure 13.30 ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type Linker, 2023-2035 (USD Million)
Figure 15.1 Concluding Remarks: Current Market Landscape of ADC Linker and Conjugation Technologies
Figure 15.2 Concluding Remarks: Patent Analysis
Figure 15.3 Concluding Remarks: Partnerships and Collaborations
Figure 15.4 Concluding Remarks: Business Model Analysis
Figure 15.5 Concluding Remarks: Current Market Landscape of ADC Therapeutics
Figure 15.6 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 3.1. Commonly Used Cytotoxins in ADC Therapeutics
Table 3.2 OEL Bands: Guidelines by SafeBridge Consultants
Table 4.1. ADC Linker and Conjugation Technologies: Overall Market Landscape
Table 4.2. ADC Conjugation Technologies: Information on Generation of Technology, Site-Specificity, Type of Conjugation and Drug Antibody Ratio
Table 4.3. ADC Conjugation Technologies: Information on Number of Steps Involved, Compatible Linker, Conjugation Chemistry and Conjugation Site
Table 4.4. ADC Linker and Linker-Payload Technologies: Information on Type of Linker and Linker Name
Table 4.5. ADC Linker and Conjugation Technologies: List of Technology Providers
Table 4.6. ADC Linker and Conjugation Technologies: List of Service Providers
Table 6.1. ADC Linkers and Conjugation Technologies: List of Profiled Companies
Table 6.2. Ambrx: Company Overview
Table 6.3. Ambrx: ADC Linkers and Conjugation Technologies Portfolio
Table 6.4. Ambrx: Antibody Drug Conjugates Portfolio
Table 6.5. Ambrx: Recent Developments and Future Outlook
Table 6.6. Catalent Biologics: Company Overview
Table 6.7. Catalent Biologics: ADC Linkers and Conjugation Technologies Portfolio
Table 6.8. Catalent Biologics: Antibody Drug Conjugates Portfolio
Table 6.9. Catalent Biologics: Recent Developments and Future Outlook
Table 6.10. Mersana Therapeutics: Company Overview
Table 6.11. Mersana Therapeutics: ADC Linkers and Conjugation Technologies Portfolio
Table 6.12. Mersana Therapeutics: Antibody Drug Conjugates Portfolio
Table 6.13. Mersana Therapeutics: Recent Developments and Future Outlook
Table 6.14. Seagen: Company Overview
Table 6.15. Seagen: ADC Linkers and Conjugation Technologies Portfolio
Table 6.16. Seagen: Antibody Drug Conjugates Portfolio
Table 6.17. Seagen: Recent Developments and Future Outlook
Table 6.18. Sutro Biopharma: Company Overview
Table 6.19. Sutro Biopharma: ADC Linkers and Conjugation Technologies Portfolio
Table 6.20. Sutro Biopharma: Antibody Drug Conjugates Portfolio
Table 6.21. Sutro Biopharma: Recent Developments and Future Outlook
Table 6.22. Antikor: Company Overview
Table 6.23. Antikor: ADC Conjugation Technology Portfolio
Table 6.24. Antikor: Antibody Drug Conjugates Portfolio
Table 6.25. Antikor: Recent Developments and Future Outlook
Table 6.26. Iksuda Therapeutics: Company Overview
Table 6.27. Iksuda Therapeutics: ADC Linkers and Conjugation Technologies Portfolio
Table 6.28. Iksuda Therapeutics: Antibody Drug Conjugates Portfolio
Table 6.29. Heidelberg Pharma: Company Overview
Table 6.30. Heidelberg Pharma: ADC Linkers and Conjugation Technologies Portfolio
Table 6.31. Heidelberg Pharma: Antibody Drug Conjugates Portfolio
Table 6.32. Heidelberg Pharma: Recent Developments and Future Outlook
Table 6.33. LinXis: Company Overview
Table 6.34. LinXis: ADC Conjugation Technology Portfolio
Table 6.35. NBE-Therapeutics: Company Overview
Table 6.36. NBE-Therapeutics: ADC Linkers and Conjugation Technologies Portfolio
Table 6.37. NBE-Therapeutics: Antibody Drug Conjugates Portfolio
Table 6.38. Alteogen: Company Overview
Table 6.39. Alteogen: ADC Linkers and Conjugation Technologies Portfolio
Table 6.40. Alteogen: Antibody Drug Conjugates Portfolio
Table 6.41. LegoChem Biosciences: Company Overview
Table 6.42. LegoChem Biosciences: ADC Linkers and Conjugation Technologies Portfolio
Table 6.43. LegoChem Biosciences: Antibody Drug Conjugates Portfolio
Table 6.44. LegoChem Biosciences: Recent Developments and Future Outlook
Table 7.1. Patent Analysis: Top CPC Sections
Table 7.2. Patent Analysis: Top CPC Symbols
Table 7.3. Patent Analysis: Top CPC Codes
Table 7.4. Patent Analysis: Summary of Benchmarking Analysis
Table 7.5. Patent Analysis: Categorization based on Weighted Valuation Scores
Table 7.6. Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 8.1. ADC Linker and Conjugation Technologies: Partnerships and Collaborations
Table 8.2. ADC Linker and Conjugation Technologies: Partnerships and Collaborations, Information on Type of Partner, Therapeutic Area(s) and Type of Agreement (Region-wise and Geography-wise)
Table 9.1. ADC Linker and Conjugation Technologies: Business Model Analysis
Table 10.1. North America: Most Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.2. North America: Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.3. North America: Less Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.4. North America: Least Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.5. Europe: Most Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.6. Europe: Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.7. Europe: Less Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.8. Europe: Least Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.9. Asia-Pacific and Rest of the World: Most Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.10. Asia-Pacific and Rest of the World: Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.11. Asia-Pacific and Rest of the World: Less Likely Partners for ADC Linker and Conjugation Technology Providers
Table 10.12. Asia-Pacific and Rest of the World: Least Likely Partners for ADC Linker and Conjugation Technology Providers
Table 12.1. Antibody Drug Conjugates: Information on Drug Candidates, Developer(s), Stage of Development, Target Disease Indication(s) and Therapeutics Area(s)
Table 12.2. Antibody Drug Conjugates: Information on Drug Candidates, Line of Treatment, Dosage Frequency, Type of Therapy, Target Antigen and Antibody Isotype
Table 12.3. Antibody Drug Conjugates: Information on Drug Candidates, Payload / Cytotoxin / Warhead, Type of Payload, Linker and Type of Linker (Cleavable and Non-Cleavable)
Table 12.4. Antibody Drug Conjugate Developers: Information on Year of Establishment, Company Size, Location of Headquarters
Table 13.1. Technology Licensing Deal: Tranches of Milestone Payments
Table 13.2. ADC Linker and Conjugation Technologies: Average Upfront Payments and Average Milestone Payments (USD Million)
Table 14.1 Abzena: Company Snapshot
Table 14.2. MedLink Therapeutics: Company Snapshot
Table 14.3 Merck KGaA: Company Snapshot
Table 14.4 Singzyme: Company Snapshot
Table 14.5 Ajinomoto: Company Snapshot
Table 14.6 Eucodis Bioscience: Company Snapshot
Table 14.7 NBE-Therapeutics: Company Snapshot
Table 14.8 Shanghai Miracogen: Company Snapshot
Table 14.9 Synaffix: Company Snapshot
Table 16.1 ADC Linker and Conjugation Technologies: Distribution by Type of Technology
Table 16.2 ADC Linker and Conjugation Technologies: Distribution by Availability of Licensing
Table 16.3 ADC Conjugation Technologies: Distribution by Generation of Technology
Table 16.4 ADC Conjugation Technologies: Distribution by Site Specificity
Table 16.5 ADC Conjugation Technologies: Distribution by Type of Conjugation
Table 16.6 ADC Conjugation Technologies: Distribution by Drug Antibody Ratio
Table 16.7 ADC Conjugation Technologies: Distribution by Compatible Linker
Table 16.8 ADC Conjugation Technologies: Distribution by Conjugation Chemistry
Table 16.9 ADC Conjugation Technologies: Distribution by Conjugation Site
Table 16.10 ADC Linker and ADC Linker-Payload Technologies: Distribution by Type of Linker
Table 16.11 ADC Linker and Conjugation Technology Providers: Distribution by Year of Establishment
Table 16.12 ADC Linker and Conjugation Technology Providers: Distribution by Company Size
Table 16.13 ADC Linker and Conjugation Technology Providers: Distribution by Location of Headquarters
Table 16.14 ADC Linker and Conjugation Technology Providers: Distribution by Year of Establishment and Location of Headquarters
Table 16.15 ADC Linker and Conjugation Technology Providers: Distribution by Company Size and Location of Headquarters
Table 16.16 Ambrx: Annual Revenues, 2020-2022 (USD Million)
Table 16.17 Mersana Therapeutics: Annual Revenues, 2018-2022 (USD Million)
Table 16.18 Seagen: Revenues, 2018-2022 (USD Billion)
Table 16.19 Sutro Biopharma: Revenues, 2018 - 2022 (KRW Billion)
Table 16.20 Heidelberg Pharma: Annual Revenues, 2018-2022 (EUR Million)
Table 16.21 Catalent Biologics: Revenues, 2018- 2022 (USD Billion)
Table 16.22 Patent Analysis: Distribution by Type of Patent
Table 16.23 Patent Analysis: Cumulative Distribution by Publication Year
Table 16.24 Patent Analysis: Cumulative Distribution by Application Year
Table 16.25 Patent Analysis: Distribution by Patent Type and Publication Year
Table 16.26 Patent Analysis: Distribution by Patent Jurisdiction
Table 16.27 Patent Analysis: Distribution by CPC Symbols and Sections
Table 16.28 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
Table 16.29 Leading Industry Players: Distribution by Number of Patents
Table 16.30 Leading Non-Industry Players: Distribution by Number of Patents
Table 16.31 Leading Individual Assignees: Distribution by Number of Patents
Table 16.32 Patent Benchmarking Analysis: Distribution of Leading Industry Player by Patent Characteristics (CPC Codes)
Table 16.33 Patent Analysis: Distribution by Patent Age
Table 16.34 ADC Linker and Conjugation Technologies: Patent Valuation
Table 16.35 Partnerships and Collaborations: Distribution by Year of Partnership
Table 16.36 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.37 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
Table 16.38 Partnerships and Collaborations: Distribution by Type of Partnership and Generation of Technology
Table 16.39 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Linker
Table 16.40 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Conjugation
Table 16.41 Partnerships and Collaborations: Distribution by Type of Partner
Table 16.42 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 16.43 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 16.44 Partnerships and Collaborations: Distribution by Therapeutic Area(s)
Table 16.45 Most Active Players: Distribution by Number of Partnerships
Table 16.46 Most Popular Technologies: Distribution by Number of Partnerships
Table 16.47 Partnership and Collaborations: Local and International Agreements
Table 16.48 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 16.49 Business Models Analysis: Distribution by Purpose of Partnership
Table 16.50 Business Models Analysis: Distribution by Year of Partnership and Purpose of Partnership
Table 16.51 Business Models Analysis: Distribution by Type of Business Strategy Adopted
Table 16.52 Business Models Analysis: Distribution by Purpose of Partnership and Type of Business Strategy Adopted
Table 16.53 Business Models Analysis: Distribution by Upfront and Milestone Payments
Table 16.54 Business Models Analysis: Distribution by Type of Business Model Adopted and Deal Value
Table 16.55 Synaffix: Distribution by Purpose of Partnership
Table 16.56 Synaffix: Technology Out-Licensing Deals by Deal Value
Table 16.57 LegoChem Biosciences: Distribution by Purpose of Partnership
Table 16.58 LegoChem Biosciences: Distribution by Year of Partnership and Business Strategy Adopted
Table 16.59 LegoChem Biosciences: Distribution of Technology Out-Licensing Deals by Deal Value
Table 16.60 Catalent Biologics: Distribution by Purpose of Partnership
Table 16.61 Catalent Biologics: Distribution by Year of Partnership and Business Strategy Adopted
Table 16.62 Sutro Biopharma: Distribution by Purpose of Partnership
Table 16.63. Sutro Biopharma: Distribution by Year of Partnership and Business Strategy Adopted
Table 16.64. Sutro Biopharma: Distribution of Technology Out-Licensing Deals by Deal Value
Table 16.65. Heidelberg Pharma: Distribution by Purpose of Partnership
Table 16.66. Heidelberg Pharma: Distribution by Year of Partnership and Business Strategy Adopted
Table 16.67. Mersana Therapeutics: Distribution by Purpose of Partnership
Table 16.68. Mersana Therapeutics: Distribution by Year of Partnership and Business Strategy Adopted
Table 16.69. Antibody Drug Conjugates: Distribution by Stage of Development
Table 16.70. Antibody Drug Conjugates: Distribution by Target Disease Indication
Table 16.71. Antibody Drug Conjugates: Distribution by Therapeutic Area(s)
Table 16.72. Antibody Drug Conjugates: Distribution by Line of Treatment
Table 16.73. Antibody Drug Conjugates: Distribution by Dosing Frequency
Table 16.74. Antibody Drug Conjugates: Distribution by Type of Therapy
Table 16.75. Antibody Drug Conjugates: Distribution by Target Antigen
Table 16.76. Antibody Drug Conjugates: Distribution by Antibody Isotype
Table 16.77. Antibody Drug Conjugates: Distribution by Type of Cytotoxin / Warhead
Table 16.78. Antibody Drug Conjugates: Distribution by Type of Payload
Table 16.79. Antibody Drug Conjugates: Distribution by Linker
Table 16.80 Antibody Drug Conjugates: Distribution by Type of Linker
Table 16.81. Antibody Drug Conjugate Developers: Distribution by Year of Establishment
Table 16.82. Antibody Drug Conjugates Developers: Distribution by Company Size
Table 16.83. Antibody Drug Conjugates Developers: Distribution by Location of Headquarters
Table 16.84. Antibody Drug Conjugates Developers: Distribution by Company Size and Location of Headquarters
Table 16.85. Most Active Players: Distribution by Number of Antibody Drug Conjugates
Table 16.86 Global ADC Linker and Conjugation Technologies Market, Conservative, Base and Optimistic Scenarios, 2017-2035 (USD Million)
Table 16.87 ADC Linker and Conjugation Technologies Market: Distribution by Generation of Technology, 2023 and 2035
Table 16.88 ADC Linker and Conjugation Technologies Market for Third-Generation Technologies, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.89 ADC Linker and Conjugation Technologies Market for Second-Generation Technologies, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.90 ADC Linker and Conjugation Technologies Market for Next-Generation Technologies, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.91 ADC Linker and Conjugation Technologies Market: Distribution by Type of Conjugation, 2023 and 2035
Table 16.92 ADC Linker and Conjugation Technologies Market for Chemical Conjugation, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.93 ADC Linker and Conjugation Technologies Market for Chemoenzymatic Conjugation, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.94 ADC Linker and Conjugation Technologies Market for Enzymatic Conjugation, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.95 ADC Linker and Conjugation Technologies Market: Distribution by Type of Linker, 2023 and 2035
Table 16.96 ADC Linker and Conjugation Technologies Market for Cleavable Linkers, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.97 ADC Linker and Conjugation Technologies Market for Non-Cleavable Linkers, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.98 ADC Linker and Conjugation Technologies Market: Distribution by Type of Payment Model Adopted, 2023 and 2035
Table 16.99 ADC Linker and Conjugation Technologies Market for Upfront Payments, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.100 ADC Linker and Conjugation Technologies Market for Milestone Payments, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.101 ADC Linker and Conjugation Technologies Market: Distribution by Key Geographical Regions, 2023 and 2035
Table 16.102 ADC Linker and Conjugation Technologies Market in North America, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.103 ADC Linker and Conjugation Technologies Market in North America: Distribution by Generation of Technology, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.104 ADC Linker and Conjugation Technologies Market in North America: Distribution by Type of Conjugation, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.105 ADC Linker and Conjugation Technologies Market in North America: Distribution by Type Linker 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.106 ADC Linker and Conjugation Technologies Market in Europe, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.107 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Generation of Technology, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.108 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type of Conjugation, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.109 ADC Linker and Conjugation Technologies Market in Europe: Distribution by Type Linker 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.110 ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.111 ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Generation of Technology, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.112 ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type of Conjugation, 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)
Table 16.113 ADC Linker and Conjugation Technologies Market in Asia-Pacific and Rest of the World: Distribution by Type Linker 2023-2035, Conservative, Base and Optimistic Scenarios (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report:

 

  1. 2BScientific
  2. 3SBio
  3. Ab Studio
  4. AbbVie
  5. Abcam
  6. AbClon
  7. ABL Bio
  8. Abnova
  9. AbTis
  10. Abzena
  11. ACES Pharma
  12. Adagene
  13. ADC Biotechnology
  14. ADC Therapeutics
  15. Adcendo
  16. Adcentrx Therapeutics
  17. Advanced Proteome Therapeutics
  18. Affinity Life Sciences
  19. AGC Biologics
  20. Agensys
  21. AIMEDBIO
  22. Ajinomoto
  23. Albumedix
  24. Allozyne
  25. Alpha Cancer Technologies
  26. Alphamab Oncology
  27. AlphaThera
  28. Alteogen
  29. AltruBio (formerly known as AbGenomics)
  30. Ambrx
  31. Amgen
  32. Angiex
  33. Antengene
  34. Antikor
  35. Apexigen
  36. Aptamer
  37. Araris Biotech
  38. Asana BioSciences
  39. Astellas Pharma
  40. AstraZeneca
  41. Atara Biotherapeutics
  42. ATB Therapeutics
  43. Atreca
  44. Avacta
  45. Avipep Therapeutics
  46. Bayer
  47. BeiGene
  48. Bicycle Therapeutics
  49. Binghamton University
  50. BioAtla
  51. Biocytogen
  52. BioLegend
  53. BioMed Valley Discoveries
  54. BiOneCure Therapeutics
  55. BioNova Pharmaceuticals
  56. BioOutsource
  57. Bio-Rad
  58. Biosion
  59. Biosynth
  60. Bio-Synthesis
  61. BioTechnique
  62. Bio-Thera Solutions
  63. BIOZOL
  64. BiVictriX Therapeutics
  65. Bliss Biopharmaceutical
  66. BOC Sciences
  67. Boehringer Ingelheim
  68. Bolt Biotherapeutics
  69. Boster Bio
  70. Boston College
  71. BrickBio
  72. Bristol-Myers Squibb
  73. BSP Pharmaceuticals
  74. Byondis
  75. Cancer Research UK
  76. Capra Science
  77. CARBOGEN AMCIS
  78. Cardinal Health
  79. Catalent Biologics
  80. CEL Healthcare Fund
  81. Celgene
  82. Cell Signalling Technology
  83. Cellectar Biosciences
  84. CellMosaic
  85. Celltrion
  86. Centrose
  87. Cerbios-Pharma
  88. Charite – Universitatsmedizin Berlin
  89. Chiome Bioscience
  90. Chong Kun Dang Pharmaceutical
  91. Constellation Pharmaceuticals
  92. Corbus Pharmaceuticals
  93. Creative Biolabs
  94. Creative Diagnostics
  95. Creative Peptides
  96. Cristal Therapeutics
  97. CSPC Pharmaceutical
  98. CStone Pharmaceuticals
  99. CT Pharma and Biotechnology Research and Development
  100. CureMeta
  101. CytomX Therapeutics
  102. Daiichi Sankyo
  103. Dakewe
  104. Dalton Pharma Services
  105. Dantari
  106. Debiopharm
  107. Diatheva
  108. DualityBio
  109. Eisai
  110. Elevation Oncology
  111. EMD Serono
  112. Emergence Therapeutics
  113. Envigo
  114. EUCODIS Bioscience
  115. Everest Biotech
  116. Exelixis
  117. Expedeon
  118. Femtogenix
  119. Fleet Bioprocessing
  120. Formosa Laboratories
  121. Formosa Pharmaceuticals
  122. Fortis Therapeutics
  123. Fosun Pharma
  124. Fudan University
  125. Funakoshi
  126. Genentech
  127. GeneQuantum Healthcare
  128. Genmab
  129. Genor Biopharma
  130. Genovis
  131. GenScript
  132. Genzyme
  133. Gilead Sciences
  134. Glycotope
  135. Glykos
  136. Goodwin Biotechnology
  137. GlaxoSmithKline
  138. Hangzhou Adcoris Biopharma
  139. Hangzhou DAC Biotech
  140. Hansoh Pharma
  141. Harbour BioMed
  142. Heidelberg Pharma
  143. Hisun Pharmaceuticals
  144. HOPU Investments
  145. Hummingbird Bioscience
  146. iBIOSOURCE
  147. Iconic Therapeutics
  148. Iksuda Therapeutics (formerly known as Glythera)
  149. ImmuneOncia Therapeutics
  150. ImmunoBiochem
  151. ImmunoGen
  152. Immunome
  153. Immunomedics
  154. Innate Pharma
  155. INNOVATE
  156. Innovent Biologics
  157. Interchim
  158. IntoCell
  159. Intravacc
  160. IONTAS
  161. iProgen Biotech
  162. Janssen Biotech
  163. Janssen Pharmaceuticals
  164. Jazz Pharmaceuticals
  165. Kairos Therapeutics
  166. KLUS Pharma
  167. Kyowa Hakko Kirin
  168. LabClinics
  169. LakePharma
  170. LaNova Medicines
  171. Lantheus
  172. Laronde
  173. LegoChem Biosciences
  174. Leinco Technologies
  175. Lepu Biopharma
  176. Levena Biopharma
  177. Light Chain Bioscience
  178. LinXis
  179. Lonza
  180. Lundbeck
  181. Luzsana Biotechnology
  182. Mablink
  183. MabPlex
  184. MabSpace Biosciences
  185. Mabwell
  186. MacroGenics
  187. Magenta Therapeutics
  188. Maine Biotechnology
  189. McSAF
  190. medac
  191. MediaPharma
  192. MediLink Therapeutics
  193. MedImmune
  194. Meditope Biosciences
  195. MedKoo Biosciences
  196. Megalith Pharmaceuticals
  197. Menarini
  198. Merck KGaA
  199. Mersana Therapeutics
  200. Millennium Pharmaceuticals
  201. Mitsubishi Tanabe Pharma
  202. Momenta Pharmaceuticals
  203. Multitude Therapeutics
  204. MuseChem
  205. Mythic Therapeutics
  206. NanoValent Pharmaceuticals
  207. National Cancer Center Research Institute Japan
  208. National Cancer Institute
  209. National Research Council Canada
  210. Navrogen
  211. NBE-Therapeutics (acquired by Boehringer Ingelheim)
  212. Nektar Therapeutics
  213. Nerviano Medical Sciences
  214. NextCure
  215. Nordic Nanovector
  216. Noria Therapeutics
  217. NovaRock Biotherapeutics
  218. Novartis
  219. Novatein Biosciences
  220. Novelty Nobility
  221. NovoCodex Biopharmaceuticals
  222. Novozymes
  223. OBI Pharma
  224. OcyonBio
  225. OGD2 Pharma
  226. Oncolinx
  227. Oncomatryx
  228. Oncotec Pharma Produktion
  229. OnCusp Therapeutics
  230. Orano Med
  231. OriGene
  232. OS Therapies
  233. Oxford BioTherapeutics
  234. Paul Scherrer Institute
  235. Peak Bio
  236. Perseus Proteomics
  237. Pfizer
  238. Pharmaron
  239. Pheon Therapeutics
  240. Pierre Fabre
  241. PinotBio
  242. Pioneering Medicines
  243. Piramal Pharma Solutions
  244. PolyTherics
  245. Principia Biopharma
  246. ProBioGen
  247. ProfoundBio
  248. Progenics Pharmaceuticals
  249. ProteoGenix
  250. Pyxis Oncology
  251. Quadira Biosciences
  252. Quartzy
  253. Rakuten Medical
  254. Recepta Biopharma
  255. Redwood Bioscience
  256. Regeneron
  257. RemeGen Biosciences
  258. Revance Therapeutics
  259. Roche
  260. Rocket Pharmaceuticals
  261. Rockland Immunochemicals
  262. Sanofi
  263. Sapphire Bioscience
  264. Sapporo Medical University
  265. SATT Conectus
  266. Schengen Pharma
  267. Scripps Research
  268. Seagen
  269. Seramun Diagnostica
  270. Shanghai Fosun Pharmaceutical
  271. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
  272. Shanghai Institute of Materia Medica
  273. Shanghai Miracogen
  274. Shanghai Pharma Biotherapeutics
  275. Singzyme
  276. Sinotau Pharmaceutical
  277. Sorrento Therapeutics
  278. SOTIO
  279. SouthernBiotech
  280. Spirea
  281. Sungwoo LifeSciences
  282. Sunomix Therapeutics
  283. Sutro Biopharma
  284. Synaffix
  285. Syndivia
  286. Syngene
  287. Synthon
  288. SystImmune
  289. Takeda
  290. Takeda Oncology
  291. Tanabe Research Laboratories
  292. Targinta (a subsidiary of Xintela)
  293. Tasly Biopharmaceuticals
  294. TBD Pharmatech (formerly known as TBD-Biodiscovery)
  295. The Academy of Military Science
  296. The Johns Hopkins University School of Medicine
  297. ThioLogics
  298. Toray
  299. TOT Biopharm
  300. TRIO Pharmaceuticals
  301. Triphase Accelerator
  302. Tsuchikama Laboratory
  303. Tubulis
  304. Ubix Therapeutics
  305. UCB
  306. University College London
  307. University Medical Center Groningen
  308. Vaccinex
  309. Vall d’Hebrón Institute of Oncology
  310. Vall d’Hebron University Hospital
  311. Vaxcyte
  312. Vector Laboratories
  313. Vincerx Pharma
  314. Welsh, Carson, Anderson & Stowe
  315. WuXi PharmaTech
  316. Y-Biologics
  317. Zhejiang Teruisi Pharmaceutical
  318. ZIP Solutions
  319. Zydus
  320. Zymeworks

Source 1: https://pubs.rsc.org/en/content/articlehtml/2017/sc/c6sc05149a
Source 2: https://aacrjournals.org/clincancerres/article/17/20/6389/76679/Antibody-Conjugate-Therapeutics-Challenges-and

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com